AVITA Medical Q1 revenue $18.5M (+67% YoY); reaffirms FY guidance $100-106M

AVITA Medical, Inc.

2025-Q1 EPS reported -$0.53 revenue$18,514,000

Net loss of $13.9M ($0.53/sh) improved from $18.7M loss ($0.73/sh) in Q1 2024.
Gross profit margin 84.7%; RECELL-only margin 86.4%; expects ~$2.5M lower quarterly opex going forward.
Launched RECELL GO mini in Feb; nationwide Cohealyx launch on Apr 1 expanding addressable U.S. market to >$3.5B.
Obtained OrbiMed revenue covenant waiver for Q1; Q2 trailing 12-month covenant set at $78.0M.
Expects to generate free cash flow in H2 2025 and achieve GAAP profitability in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.